Dovato
Payments companies reported to CMS as associated with Dovato. "Associated with" is CMS's wording: it links a payment to a product without saying the money was spent on it.
By year
Payments reported as associated with Dovato, per program year, as reported to CMS.
Who makes it
Specialties most often involved
Where the associated payments went, by the receiving clinician's specialty.
Clinicians most associated with Dovato
These are the largest totals companies reported as associated with Dovato. They are typically speaking or consulting arrangements, which companies must report by law; appearing here is not evidence of anything improper.
| Clinician | Location | Specialty | Associated payments (2023-2025) |
|---|---|---|---|
| Elizabeth Race | Dallas, TX | Infectious Disease | $286,064.79 |
| Nelson Vallejo | Las Piedras, PR | Internal Medicine | $267,810.39 |
| Tulika Singh | Orange, CA | Infectious Disease | $262,746.06 |
| Ogechika Alozie | El Paso, TX | Infectious Disease | $217,758.81 |
| Bisher Akil | New York, NY | Pulmonary Disease | $194,126.40 |
| Marc Tribble | Dallas, TX | Internal Medicine | $192,212.06 |
| Zandraetta Tims-Cook | Atlanta, GA | Infectious Disease | $168,238.10 |
| Stephen Adams | Springfield, MO | Family Medicine | $167,065.13 |
| Jihad Slim | Newark, NJ | Infectious Disease | $162,978.27 |
| Gary Blick | Norwalk, CT | Internal Medicine | $155,074.54 |
Prescribed Dovato?
See what its makers reported for your doctor. Two steps, private, no account.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.